Ser83
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser83  -  PLM (dog)

Site Information
EEGTFRSsIRRLstR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 451424

In vivo Characterization
Methods used to characterize site in vivo:
mutation of modification site ( 1 , 3 , 4 ) , phospho-antibody ( 1 , 3 ) , western blotting ( 1 , 3 )
Relevant cell line - cell type - tissue:
HeLa (cervical) ( 1 ) , myocyte-heart ( 4 ) , oocyte ( 3 )

Upstream Regulation
Putative in vivo kinases:
PKCA (human) ( 1 )
Kinases, in vitro:
PKACA (human) ( 2 ) , PKCA (human) ( 2 ) , PKCE (human) ( 2 )
Treatments:
phorbol_ester ( 1 ) , PP1 ( 1 )

Downstream Regulation
Effects of modification on PLM:
activity, induced ( 3 )

References 

1

Han F, et al. (2010) Role of phospholemman phosphorylation sites in mediating kinase-dependent regulation of the Na+-K+-ATPase. Am J Physiol Cell Physiol 299, C1363-9
20861470   Curated Info

2

Fuller W, et al. (2009) FXYD1 phosphorylation in vitro and in adult rat cardiac myocytes: threonine 69 is a novel substrate for protein kinase C. Am J Physiol Cell Physiol 296, C1346-55
19339511   Curated Info

3

Bibert S, et al. (2008) Phosphorylation of phospholemman (FXYD1) by protein kinases A and C modulates distinct Na,K-ATPase isozymes. J Biol Chem 283, 476-86
17991751   Curated Info

4

Song J, et al. (2005) Serine 68 of phospholemman is critical in modulation of contractility, [Ca2+]i transients, and Na+/Ca2+ exchange in adult rat cardiac myocytes. Am J Physiol Heart Circ Physiol 288, H2342-54
15653756   Curated Info